48,833
edits
Difference between revisions of "Cytokeratin 5/6"
Jump to navigation
Jump to search
→Positive
| Line 9: | Line 9: | ||
==Positive== | ==Positive== | ||
*[[Squamous cell carcinoma]]. | *[[Squamous cell carcinoma]]. | ||
**[[Squamous cell carcinoma of the lung]].<ref name=pmid26273374>{{Cite journal | last1 = Ma | first1 = Y. | last2 = Fan | first2 = M. | last3 = Dai | first3 = L. | last4 = Kang | first4 = X. | last5 = Liu | first5 = Y. | last6 = Sun | first6 = Y. | last7 = Xiong | first7 = H. | last8 = Liang | first8 = Z. | last9 = Yan | first9 = W. | title = Expression of p63 and CK5/6 in early-stage lung squamous cell carcinoma is not only an early diagnostic indicator but also correlates with a good prognosis. | journal = Thorac Cancer | volume = 6 | issue = 3 | pages = 288-95 | month = May | year = 2015 | doi = 10.1111/1759-7714.12181 | PMID = 26273374 }}</ref> | |||
*Benign prostate (basal cells).<ref name=pmid19605815>{{Cite journal | last1 = Trpkov | first1 = K. | last2 = Bartczak-McKay | first2 = J. | last3 = Yilmaz | first3 = A. | title = Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens. | journal = Am J Clin Pathol | volume = 132 | issue = 2 | pages = 211-20; quiz 307 | month = Aug | year = 2009 | doi = 10.1309/AJCPGFJP83IXZEUR | PMID = 19605815 }}</ref> | *Benign prostate (basal cells).<ref name=pmid19605815>{{Cite journal | last1 = Trpkov | first1 = K. | last2 = Bartczak-McKay | first2 = J. | last3 = Yilmaz | first3 = A. | title = Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens. | journal = Am J Clin Pathol | volume = 132 | issue = 2 | pages = 211-20; quiz 307 | month = Aug | year = 2009 | doi = 10.1309/AJCPGFJP83IXZEUR | PMID = 19605815 }}</ref> | ||
*[[Urothelial carcinoma]]. | *[[Urothelial carcinoma]]. | ||